Pectoralis Minor Release Versus Non-release in RSA
Launched by EMORY UNIVERSITY · Mar 2, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating whether a surgical procedure called pectoralis minor release can help improve pain and movement after a type of shoulder surgery known as Reverse Total Shoulder Arthroplasty (RSA). The study aims to find out if releasing this muscle before the surgery can lead to better pain relief, greater range of motion, and higher satisfaction scores from patients after the operation. Participants will be randomly assigned to either have the RSA surgery with the muscle release or without it.
To be eligible for the trial, participants must be adults planning to have Reverse Total Shoulder Arthroplasty and should be able to give informed consent. Unfortunately, individuals who are undergoing a different type of shoulder surgery, are minors, pregnant, or unable to consent will not be included. If you decide to participate, you will have the opportunity to contribute to important research that may help improve shoulder surgery outcomes for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients undergoing surgery for reverse total shoulder arthroplasty
- • Patients willing and able to provide informed consent
- Exclusion Criteria:
- • Revision arthroplasty
- • Reverse shoulder arthroplasty for proximal humerus fractures
- • Adults unable to consent
- • Individuals who are not yet adults (infants, children, teenagers)
- • Pregnant women
- • Prisoners
About Emory University
Emory University, a leading research institution located in Atlanta, Georgia, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, Emory harnesses the expertise of its renowned faculty and state-of-the-art facilities to conduct cutting-edge research across various fields, including oncology, neurology, and infectious diseases. The university's commitment to ethical research practices and patient safety ensures that all clinical trials are designed to generate valuable data that can lead to significant therapeutic advancements. By fostering partnerships with local hospitals and community organizations, Emory strives to translate research findings into real-world applications, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Atlanta, Georgia, United States
Patients applied
Trial Officials
Eric Wagner, MD
Principal Investigator
Emory University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported